BMS 687681 - Bristol-Myers Squibb

Drug Profile

BMS 687681 - Bristol-Myers Squibb

Alternative Names: BMS-687681; CCR2/5 antagonist - Bristol-Myers Squibb; CCR2/5 dual antagonist

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Cardiovascular therapies; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Discontinued Cardiovascular disorders; Immunological disorders

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical studies in Cancer presented at the at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 28 Dec 2017 Discontinued - Preclinical for Immunological disorders in USA (Bristol-Myers Squibb pipeline, December 2017)
  • 13 Oct 2017 Phase-I clinical trials in Cancer in USA before October 2017 (Bristol-Myers Squibb pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top